ISSUE:
Whether Cipla’s product, ‘Erlocip’ which is Polymorph B of the compound ‘Erlotinib’ encroaches Roche’s patented compound ‘Erlotinib’.
Whether Roche’s patented compound ‘Erlotinib’ is a legitimate patent?
RULE:
The compound of a drug might exist in different polymorphic designs; nonetheless, any such designs will be subsumed inside the patent.